GlassScriptPhysician profile
Christopher Della Rocca
NPI 1760995252
$6,381.63
in general payments reported to CMS, 2019-2025
31 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $879 · 2022: $1,104 · 2023: $1,508 · 2024: $1,740 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,397.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,059.78 | 2021-2025 | |
| Novo Nordisk INC | $783.68 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $552.00 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $526.46 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $479.99 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $383.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $365.75 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.06 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $228.02 | 2022 | |
| Daiichi Sankyo INC. | $205.77 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $205.44 | 2022-2023 | |
| Exact Sciences Corporation | $171.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $164.42 | 2021-2025 | Lagevrio, Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $150.14 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $97.76 | 2024-2025 | Inspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $91.25 | 2021-2023 | Austedo Xr, Austedo |
| Astellas Pharma US INC | $87.19 | 2024 | Veozah |
| Abbott Laboratories | $75.46 | 2022-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $67.10 | 2021-2025 | Nexletol |
| Sanofi Pasteur INC. | $66.26 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $53.38 | 2024 | Eliquis |
| Seqirus USA INC | $46.63 | 2022-2025 | Fluad, Flucelvax |
| Amarin Pharma, INC. | $35.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.30 | 2021-2024 | Spravato |
| Dynavax Technologies Corporation | $27.78 | 2023 | Heplisav-B |
| Genentech USA, INC. | $26.30 | 2021 | |
| Averitas Pharma INC. | $23.01 | 2024 | Qutenza |
| Axsome Therapeutics, INC. | $21.18 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $17.30 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.27 | 2023 | Strensiq |
| Neos Therapeutics, LP | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Della Rocca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.